Eli Lilly Terminates Key Collaboration Agreement for RIPK1 Inhibitor ocadusertib
Summary
Eli Lilly has terminated its collaboration agreement with Rigel Pharmaceuticals for the RIPK1 inhibitor ocadusertib, eliminating future milestone and royalty payments for Rigel.
Key Events
-
Collaboration Agreement Terminated
Eli Lilly and Company has terminated its License and Collaboration Agreement with Rigel Pharmaceuticals, Inc., effective June 15, 2026.
-
Loss of Future Milestones and Royalties
Rigel will no longer receive potential milestone payments or royalties from Lilly for ocadusertib and other RIPK1 inhibitors.
-
Regains Full Rights to Program
Rigel Pharmaceuticals will regain full worldwide rights to ocadusertib and related RIPK1 inhibitor programs upon termination.
-
Prior CNS Program Termination
This termination follows the earlier cessation of the CNS disease program under the same agreement in November 2025.
Analysis
Rigel Pharmaceuticals faces a significant setback as Eli Lilly terminates their collaboration agreement for ocadusertib, a promising RIPK1 inhibitor. This termination means Rigel will no longer receive potential milestone payments or royalties, impacting its future revenue streams and development funding. While Rigel regains full rights to the program, it now bears the entire financial burden and risk of further development, potentially requiring substantial capital investment or a new partnership. This follows a prior termination of the CNS disease program under the same agreement, signaling a complete withdrawal of Lilly's involvement.
At the time of this filing, RIGL was trading at $31.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $596.5M. The 52-week trading range was $16.43 to $52.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.